Do analysts rate NUWE or IRIX?

IRIDEX has a consensus price target of $3.00, suggesting a potential upside of 376.19%. Given IRIDEX's stronger consensus rating and higher probable upside, analysts clearly believe IRIDEX is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IRIDEX 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, NUWE or IRIX?

IRIDEX has higher revenue and earnings than Nuwellis. IRIDEX is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $9.01M 0.33 -$17.52M -$132.59 N/A IRIDEX $52.67M 0.21 -$4.44M -$0.20 N/A

Is NUWE or IRIX more profitable?

IRIDEX has a net margin of -6.88% compared to Nuwellis' net margin of -123.38%. IRIDEX's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -623.14% -147.34% IRIDEX -6.88% N/A -12.55%

Does the media prefer NUWE or IRIX?

In the previous week, IRIDEX had 1 more articles in the media than Nuwellis. MarketBeat recorded 2 mentions for IRIDEX and 1 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.16 beat IRIDEX's score of 0.06 indicating that Nuwellis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuwellis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IRIDEX 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ADGM or NUWE?

Adagio Medical presently has a consensus target price of $3.50, indicating a potential upside of 1,566.67%. Given Adagio Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Adagio Medical is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagio Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADGM or NUWE more profitable?

Adagio Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Nuwellis' return on equity of -623.14% beat Adagio Medical's return on equity. Company Net Margins Return on Equity Return on Assets Adagio Medical N/A -661.85% -73.35% Nuwellis -123.38% -623.14% -147.34%

Does the media favor ADGM or NUWE?

In the previous week, Adagio Medical had 2 more articles in the media than Nuwellis. MarketBeat recorded 3 mentions for Adagio Medical and 1 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.16 beat Adagio Medical's score of -0.01 indicating that Nuwellis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagio Medical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuwellis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NUWE or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NUWE or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Check-Cap's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -623.14% -147.34% Check-Cap N/A N/A N/A

Does the media refer more to NUWE or MBAI?

In the previous week, Nuwellis and Nuwellis both had 1 articles in the media. Nuwellis' average media sentiment score of 0.16 beat Check-Cap's score of 0.00 indicating that Nuwellis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuwellis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NDRA or NUWE?

ENDRA Life Sciences currently has a consensus price target of $25.00, suggesting a potential upside of 321.59%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe ENDRA Life Sciences is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NDRA or NUWE more profitable?

ENDRA Life Sciences has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. ENDRA Life Sciences' return on equity of -246.34% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets ENDRA Life Sciences N/A -246.34% -150.81% Nuwellis -123.38% -623.14% -147.34%

Do analysts prefer ICCM or NUWE?

IceCure Medical presently has a consensus price target of $52.50, suggesting a potential upside of 2,934.68%. Given IceCure Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe IceCure Medical is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IceCure Medical 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ICCM or NUWE more profitable?

Nuwellis has a net margin of -123.38% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets IceCure Medical -427.67% -174.26% -112.58% Nuwellis -123.38% -623.14% -147.34%

Does the media prefer ICCM or NUWE?

In the previous week, IceCure Medical and IceCure Medical both had 1 articles in the media. Nuwellis' average media sentiment score of 0.16 beat IceCure Medical's score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuwellis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nuwellis (NUWE) Competitors

$0.81 -0.04 (-4.95%)

Closing price 04:00 PM Eastern

Extended Trading

$0.80 0.00 (-0.25%)

As of 04:46 PM Eastern

Compare

NUWE vs. IRIX, ADGM, MBAI, NDRA, and ICCM

Should you buy Nuwellis stock or one of its competitors? Nuwellis's main competitors and comparable companies include IRIDEX (IRIX), Adagio Medical (ADGM), Check-Cap (MBAI), ENDRA Life Sciences (NDRA), and IceCure Medical (ICCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nuwellis compare to IRIDEX?

Nuwellis (NASDAQ:NUWE) and IRIDEX (NASDAQ:IRIX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 20.1% of IRIDEX shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 8.6% of IRIDEX shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

IRIDEX has a consensus price target of $3.00, suggesting a potential upside of 376.19%. Given IRIDEX's stronger consensus rating and higher probable upside, analysts clearly believe IRIDEX is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IRIDEX has a net margin of -6.88% compared to Nuwellis' net margin of -123.38%. IRIDEX's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
IRIDEX	-6.88%	N/A	-12.55%

In the previous week, IRIDEX had 1 more articles in the media than Nuwellis. MarketBeat recorded 2 mentions for IRIDEX and 1 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.16 beat IRIDEX's score of 0.06 indicating that Nuwellis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuwellis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IRIDEX	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

IRIDEX has higher revenue and earnings than Nuwellis. IRIDEX is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$9.01M	0.33	-$17.52M	-$132.59	N/A
IRIDEX	$52.67M	0.21	-$4.44M	-$0.20	N/A

Nuwellis has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, IRIDEX has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

IRIDEX beats Nuwellis on 13 of the 16 factors compared between the two stocks.

How does Nuwellis compare to Adagio Medical?

Adagio Medical (NASDAQ:ADGM) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Adagio Medical presently has a consensus target price of $3.50, indicating a potential upside of 1,566.67%. Given Adagio Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Adagio Medical is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

48.1% of Adagio Medical shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 7.8% of Adagio Medical shares are owned by insiders. Comparatively, 1.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Adagio Medical had 2 more articles in the media than Nuwellis. MarketBeat recorded 3 mentions for Adagio Medical and 1 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.16 beat Adagio Medical's score of -0.01 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagio Medical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuwellis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adagio Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Nuwellis' return on equity of -623.14% beat Adagio Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-661.85%	-73.35%
Nuwellis	-123.38%	-623.14%	-147.34%

Nuwellis has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	N/A	N/A	-$25.08M	-$1.48	N/A
Nuwellis	$9.01M	0.33	-$17.52M	-$132.59	N/A

Adagio Medical has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

Summary

Adagio Medical beats Nuwellis on 9 of the 15 factors compared between the two stocks.

How does Nuwellis compare to Check-Cap?

Nuwellis (NASDAQ:NUWE) and Check-Cap (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Nuwellis has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

In the previous week, Nuwellis and Nuwellis both had 1 articles in the media. Nuwellis' average media sentiment score of 0.16 beat Check-Cap's score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuwellis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Check-Cap has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Check-Cap's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
Check-Cap	N/A	N/A	N/A

Check-Cap has lower revenue, but higher earnings than Nuwellis. Check-Cap is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$9.01M	0.33	-$17.52M	-$132.59	N/A
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Check-Cap beats Nuwellis on 6 of the 11 factors compared between the two stocks.

How does Nuwellis compare to ENDRA Life Sciences?

ENDRA Life Sciences (NASDAQ:NDRA) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

ENDRA Life Sciences has higher earnings, but lower revenue than Nuwellis. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A
Nuwellis	$9.01M	0.33	-$17.52M	-$132.59	N/A

ENDRA Life Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

In the previous week, Nuwellis had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for ENDRA Life Sciences. Nuwellis' average media sentiment score of 0.16 beat ENDRA Life Sciences' score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Overall Sentiment
ENDRA Life Sciences	Neutral
Nuwellis	Neutral

ENDRA Life Sciences currently has a consensus price target of $25.00, suggesting a potential upside of 321.59%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe ENDRA Life Sciences is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ENDRA Life Sciences has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. ENDRA Life Sciences' return on equity of -246.34% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-246.34%	-150.81%
Nuwellis	-123.38%	-623.14%	-147.34%

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 1.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

ENDRA Life Sciences beats Nuwellis on 8 of the 15 factors compared between the two stocks.

How does Nuwellis compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

IceCure Medical has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

IceCure Medical has higher earnings, but lower revenue than Nuwellis. IceCure Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.95M	1.50	-$15.06M	-$8.52	N/A
Nuwellis	$9.01M	0.33	-$17.52M	-$132.59	N/A

In the previous week, IceCure Medical and IceCure Medical both had 1 articles in the media. Nuwellis' average media sentiment score of 0.16 beat IceCure Medical's score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuwellis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IceCure Medical presently has a consensus price target of $52.50, suggesting a potential upside of 2,934.68%. Given IceCure Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe IceCure Medical is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 1.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuwellis has a net margin of -123.38% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Nuwellis	-123.38%	-623.14%	-147.34%

Summary

IceCure Medical beats Nuwellis on 10 of the 15 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUWE vs. The Competition

Export

Metric	Nuwellis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.94M	$5.50B	$7.26B	$13.10B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-0.01	25.37	274.73	25.76
Price / Sales	0.33	89.95	679.56	97.70
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	0.01	5.74	10.52	6.34
Net Income	-$17.52M	$151.55M	$3.49B	$360.00M
7 Day Performance	-25.96%	-0.34%	-1.10%	-0.13%
1 Month Performance	-23.14%	-3.96%	-3.42%	-3.45%
1 Year Performance	-99.36%	5.75%	15.10%	5.46%

Nuwellis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUWE Nuwellis	0.4275 of 5 stars	$0.81 -4.9%	N/A	-99.3%	$2.94M	$9.01M	N/A	38	Analyst Forecast
IRIX IRIDEX	1.7638 of 5 stars	$0.61 -4.0%	$3.00 +394.2%	-46.7%	$11.11M	$52.67M	N/A	120	News Coverage
ADGM Adagio Medical	2.6889 of 5 stars	$0.50 +8.0%	$3.50 +601.4%	-88.8%	$10.26M	$600K	N/A	87	News Coverage Positive News Gap Up
MBAI Check-Cap	0.1977 of 5 stars	$6.33 -2.5%	N/A	N/A	$8.93M	N/A	N/A	80
NDRA ENDRA Life Sciences	1.8624 of 5 stars	$5.30 -5.4%	$25.00 +371.7%	+37.0%	$8.40M	N/A	N/A	20	Positive News Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUWE) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuwellis (NUWE) Competitors

NUWE vs. IRIX, ADGM, MBAI, NDRA, and ICCM

How does Nuwellis compare to IRIDEX?

Summary

How does Nuwellis compare to Adagio Medical?

Summary

How does Nuwellis compare to Check-Cap?

Summary

How does Nuwellis compare to ENDRA Life Sciences?

Summary

How does Nuwellis compare to IceCure Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuwellis (NUWE) Competitors

NUWE vs. IRIX, ADGM, MBAI, NDRA, and ICCM

How does Nuwellis compare to IRIDEX?

Do insiders and institutionals hold more shares of NUWE or IRIX?

Do analysts rate NUWE or IRIX?

Is NUWE or IRIX more profitable?

Does the media prefer NUWE or IRIX?

Which has higher valuation and earnings, NUWE or IRIX?

Which has more risk and volatility, NUWE or IRIX?

Summary

How does Nuwellis compare to Adagio Medical?

Do analysts rate ADGM or NUWE?

Do insiders & institutionals have more ownership in ADGM or NUWE?

Does the media favor ADGM or NUWE?

Is ADGM or NUWE more profitable?

Which has higher valuation and earnings, ADGM or NUWE?

Which has more risk & volatility, ADGM or NUWE?

Summary

How does Nuwellis compare to Check-Cap?

Which has more volatility & risk, NUWE or MBAI?

Does the media refer more to NUWE or MBAI?

Is NUWE or MBAI more profitable?

Which has preferable valuation & earnings, NUWE or MBAI?

Do analysts rate NUWE or MBAI?

Do insiders and institutionals have more ownership in NUWE or MBAI?

Summary

How does Nuwellis compare to ENDRA Life Sciences?

Which has stronger earnings and valuation, NDRA or NUWE?

Which has more volatility & risk, NDRA or NUWE?

Does the media favor NDRA or NUWE?

Do analysts prefer NDRA or NUWE?

Is NDRA or NUWE more profitable?

Do insiders & institutionals hold more shares of NDRA or NUWE?

Summary

How does Nuwellis compare to IceCure Medical?

Which has more risk & volatility, ICCM or NUWE?

Which has stronger earnings & valuation, ICCM or NUWE?

Does the media prefer ICCM or NUWE?

Do analysts prefer ICCM or NUWE?

Do insiders & institutionals hold more shares of ICCM or NUWE?

Is ICCM or NUWE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools